- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 154856, 9 pages
1-Aryl-3-[4-(thieno[3,2-d]pyrimidin-4-yloxy)phenyl]ureas as VEGFR-2 Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Molecular Modelling Studies
1Centro de Química, Escola de Ciências, Universidade do Minho, Campus de Gualtar, 4710-057 Braga, Portugal
2CIQ/Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Rua do Campo Alegre, 4169-007 Porto, Portugal
3Departamento de Bioquímica (U38-FCT), Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal
4Centro de Investigação de Montanha (CIMO), Escola Superior Agrária, Instituto Politécnico de Bragança, Campus de Santa Apolónia, Apartado 1172, 5301-855 Bragança, Portugal
Received 7 April 2013; Revised 12 June 2013; Accepted 13 June 2013
Academic Editor: Carmen Domene
Copyright © 2013 Pedro Soares et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- S. Patan, “Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling,” Journal of Neuro-Oncology, vol. 50, no. 1-2, pp. 1–15, 2000.
- J. Folkman and Y. Shing, “Angiogenesis,” The Journal of Biological Chemistry, vol. 267, no. 16, pp. 10931–10934, 1992.
- N. Ferrara, H.-P. Gerber, and J. LeCouter, “The biology of VEGF and its receptors,” Nature Medicine, vol. 9, no. 6, pp. 669–676, 2003.
- M. A. Lemmon and J. Schlessinger, “Cell signaling by receptor tyrosine kinases,” Cell, vol. 141, no. 7, pp. 1117–1134, 2010.
- S. Baka, A. R. Clamp, and G. C. Jayson, “A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis,” Expert Opinion on Therapeutic Targets, vol. 10, no. 6, pp. 867–876, 2006.
- A. Eichholz, S. Merchant, and A. M. Gaya, “Anti-angiogenesis therapies: their potential in cancer management,” Oncology Targets Therapy, vol. 3, pp. 69–82, 2010.
- D. D. Hu-Lowe, H. Y. Zou, M. L. Grazzini et al., “Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3,” Clinical Cancer Research, vol. 14, no. 22, pp. 7272–7283, 2008.
- L. Cowey, G. Sonpavde, and T. E. Hutson, “New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib,” OncoTargets and Therapy, vol. 3, pp. 147–155, 2010.
- Y. Dai, Y. Guo, R. R. Frey et al., “Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors,” Journal of Medicinal Chemistry, vol. 48, no. 19, pp. 6066–6083, 2005.
- H. R. Heyman, R. R. Frey, P. F. Bousquet et al., “Thienopyridine urea inhibitors of KDR kinase,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 5, pp. 1246–1249, 2007.
- S. Claridge, F. Raeppel, M.-C. Granger et al., “Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 9, pp. 2793–2798, 2008.
- S. Raeppel, S. Claridge, O. Saavedra et al., “N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 5, pp. 1323–1328, 2009.
- O. Saavedra, S. Claridge, L. Zhan et al., “N3-Arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases,” Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 24, pp. 6836–6839, 2009.
- “Staurosporine IC50 calculated by Invitrogen with the same FRET-based VEGFR-2 enzymatic kit used in this study,” http://tools.invitrogen.com.
- R. Costa, Â. Carneiro, A. Rocha et al., “Bevacizumab and ranibizumab on microvascular endothelial cells: a comparative study,” Journal of Cellular Biochemistry, vol. 108, no. 6, pp. 1410–1417, 2009.
- A. Rocha, I. Azevedo, and R. Soares, “Anti-angiogenic effects of imatinib target smooth muscle cells but not endothelial cells,” Angiogenesis, vol. 10, no. 4, pp. 279–286, 2007.
- G. M. Morris, H. Ruth, W. Lindstrom et al., “Software news and updates AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility,” Journal of Computational Chemistry, vol. 30, no. 16, pp. 2785–2791, 2009.
- R. M. V. Abreu, H. J. C. Froufe, M. J. R. P. Queiroz, and I. C. F. R. Ferreira, “MOLA: a bootable, self-configuring system for virtual screening using AutoDock4/Vina on computer clusters,” Journal of Cheminformatics, vol. 2, no. 1, article 10, 2010.
- “The PyMOL Molecular Graphics System, Version 1.3, Schrödinger, LLC,” September 2012, http://www.pymol.org/.